 Annexon Inc NASDAQ: ANNX posted interim data from its ongoing Phase 2 trial of ANX005 in patients with Huntingtons disease HD who completed the 24-week treatment period. Annexon is developing ANX005, its lead monoclonal antibody candidate, for a range of complement-mediated disorders, including HD. 